For how we live.
In TRIUMPH-1, a triple hormone-receptor agonist produced a 25% average weight loss at the top dose over 80 weeks, and also eased knee pain and sleep apnoea. The trial was funded by Eli Lilly.
MariTide antagonises the GIP receptor that tirzepatide switches on, yet in 592 adults it drove 12–16% weight loss over a year — and it is dosed once a month, not once a week.
EECOH-1 randomised 211 adults and found the weekly GLP-1 cut HbA1c up to 1.56 points more than placebo over 24 weeks — competitive numbers from a short, single-country, company-run trial.
In TRANSCEND-T2D-1, the triple-hormone agonist cut HbA1c up to 1.12 points beyond placebo over 40 weeks and trimmed bodyweight 15.3% at the top dose in early type 2 diabetes.
TRIUMPH-4 tested retatrutide in 445 adults with obesity and knee osteoarthritis. The weight numbers are striking. So are the discontinuation numbers sitting beside them.